4Brownlee M. The pathobiology of diabetic complications: a unifying mechanism[J]. Diabetes,2005,54(6): 1 615 -1 625.
5UK Prospective Diabetes Study Group Prospective Diabetes Study16 :Overview of 6 years'therapy of type Ⅱ diabetes,a progressive disease[J]. Diabetes, 1995,44: 1 249 - 1 258.
6Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes[ J]. N Engl J Med,2003,348(5): 383 - 393.
8Hotta N, Akanuma Y, Akanuma Y, et al. Long -term clinical effects of cpalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3 - year, multicenter, comparative Aldose Reductase Inhibitor - Diabetes Complications Trial [ J ]. Diabetes Care, 2006,29(7): 1 538-1 544.
9Ziegler D,Nowak H,Kemp ler P,et al. Treatment of syrup - tomatic diabetic polyneuropathy with the antioxidant α - lipoic acid : a meta analysisl [ J]. Diabet Med,2004,21:114 - 121.
10Kadiroglu AK, Sit D, Kayabasi H, et al. The effect of venlafaxine HCI on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus [ J ]. J Diabetes Complications, 2008,22 ( 4 ) : 241 - 245.
4Semel D,Murphy TK, Zlateva G,et aL Evaluation of the safety andefficacy of pregabalin in older patients with neuropathic pain : resultsfrom a pooled analysis of 11 clinical studies. BMC Fam Pract ,2010,5(11):85-96.
5Christine NS. Gastroretentive gabapentin ( G-GR) formulation reducesintensity of pain associated with postherpetic neuralgia ( PHN) [ J].Clin J Pain ,2012,23 :112-120.
